Caris Life SciencesvsMerck & Company

CAI and MRK stock compared: price, dividend, valuation and results, from SEC filings.

CAI

Caris Life Sciences, Inc.

$19.50

Value $5.5B

-2.21%
CAI's page

MRK

Merck & Company, Inc.

$137.75

Value $341B

-3.92%
MRK's page

Caris Life Sciences (CAI) has a market value of $5.5B and Merck & Company (MRK) $341B. Over the last year, with dividends, CAI moved -17.8% and MRK +52.7%. The P/E is 57.4 for CAI and 138.8 for MRK. Dividend yield: CAI none, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CAI$5.5B

    MRK$341B

    MRK is 62 times CAI

  • Revenue, 12 months

    CAI$1.0B

    MRK$67.4B

    MRK is 64 times CAI

  • Net income, 12 months

    CAI$96M

    MRK$2.5B

    MRK is 26 times CAI

  • Operating margin

    CAI13.4%

    MRK–

  • ROIC

    CAI11.5%

    MRK3.9%

    7.6 points apart

  • P/E

    CAI57.4

    MRK138.8

    MRK is 2.4 times CAI

  • Dividend yield

    CAI0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CAI-17.8%

MRK+52.7%

100150DecFebAprJunAugOct
Returns by period
PeriodCAIWith dividendsMRKWith dividends
1 year since November 17, 2025-17.8%Price -17.8%+52.7%Price +48.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CAICaris Life SciencesMRKMerck & Company

Valuation

CAIMRK
Valuation
Price$19.50$137.75
Market value$5.5B$341B
Enterprise value (EV)–$385B
P/E57.4138.8
P/E, 5-year median–14.8
P/B8.67.6
EV/EBIT–80.8
Free cash flow yield0.5%4.3%

Results and growth

CAIMRK
Results and growth
Revenue, 12 months$1.0B$67.4B
Net income, 12 months$96M$2.5B
Free cash flow, 12 months$29M$14.7B
Earnings per share, 12 months$0.34$0.98
Revenue growth, year on year97.0%1.3%
Revenue growth a year, past+62.9%over 2 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

CAIMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin13.4%–
Net margin9.2%3.6%
ROIC11.5%3.9%
ROE16.7%5.2%

Balance sheet

CAIMRK
Balance sheet
Cash–$9.7B
Total debt–$53.8B
Net debt / EBITDA–5.7
Interest cover3.3×2.4×

Dividends and buybacks

CAIMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield0.0%1.5%
Shareholder yield–4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CAI or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Caris Life Sciences or Merck & Company?

By market value, Merck & Company ($341B) is about 61.8 times Caris Life Sciences ($5.5B), at today's prices.

How did CAI and MRK stock do over the last 1 years?

Since November 17, 2025, CAI's price moved -17.8% and MRK's +48.3%. With dividends: CAI -17.8% (-17.8% a year), MRK +52.7% (+52.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, CAI or MRK?

The dividend yield at today's price is none for Caris Life Sciences and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of CAI and MRK?

At today's price, the P/E is 57.4 for CAI and 138.8 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Caris Life Sciences or Merck & Company?

Over the last twelve months, the net margin was 9.2% for Caris Life Sciences and 3.6% for Merck & Company, and the operating margin 13.4% and –. Revenue was $1.0B and $67.4B.

Which is the better investment, Caris Life Sciences or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.